Latest news with #EUR3.10

Business Insider

Analysts Offer Insights on Healthcare Companies: Alcon (ALC) and Innate Pharma SA (OtherIPHYF)

Analysts fell to the sidelines weighing in on Alcon (ALC – Research Report) and Innate Pharma SA (IPHYF – Research Report) with neutral ratings, indicating that the experts are neither bullish nor bearish on the stocks. Confident Investing Starts Here: Alcon (ALC) Kepler Capital analyst Maja Pataki maintained a Hold rating on Alcon on May 13 and set a price target of CHF88.00. The company's shares closed last Wednesday at $87.24. According to Pataki has 0 stars on 0-5 stars ranking scale with an average return of -13.6% and a 33.6% success rate. Pataki covers the Healthcare sector, focusing on stocks such as Tecan Group AG, Demant, and Qiagen. Currently, the analyst consensus on Alcon is a Strong Buy with an average price target of $110.11. Innate Pharma SA (IPHYF) Kepler Capital analyst Justine Telliez maintained a Hold rating on Innate Pharma SA on May 13 and set a price target of EUR3.10. The company's shares closed last Friday at $1.45, close to its 52-week low of $1.28.